A5024225341- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Glycosylation and Glycoproteins Research
- Galectins and Cancer Biology
- Mathematics and Applications
- Radiopharmaceutical Chemistry and Applications
- Cultural and Historical Studies
- Adipose Tissue and Metabolism
- Cancer, Hypoxia, and Metabolism
- Advanced Topics in Algebra
- Algebraic and Geometric Analysis
- Angiogenesis and VEGF in Cancer
- Immune Cell Function and Interaction
ABL Bio (South Korea)
2020-2025
Jeonju University
2013
Korea University of Science and Technology
2012
Genome Research Foundation
2012
Korea Research Institute of Bioscience and Biotechnology
2012
Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with other checkpoint inhibitors. Lymphocyte-activation gene 3 (LAG-3) is an inhibitory receptor involved in T exhaustion and tumor immune escape. Here, we describe ABL501, a bispecific antibody targeting LAG-3 PD-L1 modulating responses against tumors. ABL501 efficiently inhibits both pathways enhances the activation effector CD4
Tumor-targeted T cell costimulatory antibody augments antitumor immunity by enhancing tumor-killing cells within the tumor.
Background TIGIT was identified as a target immune checkpoint for overcoming resistance to PD-(L)1-blocking antibodies. However, the clinical efficacies of antibodies were moderate in monotherapy and mixed combination with PD-(L)1 4-1BB, strong inducible costimulatory receptor, is another attractive antitumor therapeutics. This study investigated whether ABL112, an Fc-competent bispecific antibody targeting 4-1BB (TIGITx4-1BB), would enhance activity via Fcγ receptor (FcγR)-mediated...
Abstract The epidermal growth factor receptor (EGFR) regulates cellular proliferation, differentiation, and survival, making it a critical target in cancer therapy. While EGFR-targeted therapies show efficacy EGFR-overexpressing cancers, their use is limited by the frequent onset of drug resistance, necessitating novel approaches. Combining EGFR inhibitors with immunotherapy, such as targeting costimulatory 4-1BB (CD137) on activated T NK cells, holds potential to improve anti-tumor...
E2-EPF ubiquitin carrier protein (UCP) stabilizes hypoxia-inducible factor-1α (HIF-1α) inducing ischemic vascular responses. Here, we investigated the effect of UCP gene transfer on therapeutic angiogenesis. Adenovirus-encoded (Ad-F-UCP) increased expression endothelial growth factor (VEGF) and fibroblast factor-2 (FGF-2) in cells mice. Conditioned media from UCP-overexpressing promoted proliferation, tubule formation, invasion human umbilical-vascular-endothelial (HUVECs), vascularization...
Abstract Overexpression/amplification of the human epidermal growth factor receptor 2 (HER2) is associated with clinically aggressive subtypes in various cancers. Currently, new HER2-targeted therapy like trastuzumab deruxtecan have improved outcomes not only for HER2-positive tumors but also HER2-low tumors. However, curing cancer patients who develop resistance to current therapies or experience unwanted side effects remains a significant challenge. Therefore, there pressing need more...
Abstract B7-H4 (B7x, VTCN1), a member of the B7-family, is overexpressed in majority cancer patients with ovarian, endometrial and breast cancers. expression was also observed tumor associated macrophages implicated as an immune checkpoint regulating T cell responses. Although normal tissues quite limited, tumor-specific response by ABL103 would minimize potential adverse effects. ABL103, Grabody-T, First-in Class bispecific antibody targeting 4-1BB augments function dual mechanism, i.e., 1)...
Abstract 4-1BB (TNFSF9, CD137) is a member of the tumor necrosis factor receptor superfamily that functions as potent costimulator to immune cells, especially T-cell. Although current 4-1BB-targeted strong agonistic antibody exhibit considerable anti-tumor effect through T cell activation, it has limitation liver toxicity. To overcome challenges targeting 4-1BB, we developed bispecific can induce tumor-directed activation. A novel HER2/4-1BB antibody, YH32367 (ABL105) targets human epidermal...
Abstract The activation of CD137, also known as 4-1BB, has been identified a promising strategy for next-generation immune therapeutics. However, cancer therapies based on activating antibodies to CD137 were discontinued by adverse events such liver toxicity. To overcome those limitations, next generation antibody therapeutics using bispecific approach developed adjusting affinity, epitope, and valency. In this study, the anti-CD137 with binding epitope in membrane-proximal region did not...
Abstract Although HER2-targeted therapies such as Herceptin® (trastuzumab) have dramatically improved outcomes for solid cancer patients with HER2 overexpression, it remains a challenge to cure the positive resistance current therapies. Therefore, new approaches need treat them. One approach would be combine immunotherapy. 4-1BB (CD137) is key costimulatory receptor expressed on activated T-cells and natural killer (NK) cells promising therapeutic target in cancer. In this study, we present...
It is an interesting problem to study fixed points of element in the holonomy group affine manifold. We compute limit a sequence projective transformations and verify relations between kernels.
Abstract ROR1, a member of the ROR (Receptor Tyrosine Kinase-Like Orphan Receptor)-family, is overexpressed in process embryo and fetal development, controls cell polarity, migration neurite growth. The expression gradually reduced as development progresses, it hardly expressed adults, but overexpression ROR1 observed various blood solid cancer cells, so classified an oncofetal gene. ABL102, First-in-Class bispecific antibody targeting 4-1BB, elicits superior T activation by tumor specific...
Abstract 4-1BB is a costimulatory receptor on activated T and NK cells, the stimulation of by natural ligand or agonistic mAb enhances cellular proliferation effector functions. Immunotherapy targeting has been tested for cancer patients; however, dose-limiting toxicities agonists restrict further clinical development. B7-H3 (CD276) overexpressed cell surface multiple cancers tumor-associated endothelial yet barely healthy adult tissues. To activity in tumors, we have developed an...
<h3>Background</h3> Epidermal growth factor receptor (EGFR) is a key in cellular proliferation, differentiation, and survival, which has been considered as main target the treatment of malignancies. Although with EGFR-targeted therapy chemotherapy improved outcomes for EGFR overexpressing cancer, its clinical application limited due to drug resistance. Therefore, there an urgent <i>unmet</i> medical <i>need new</i> therapies that can <i>overcome resistance</i>, particularly cancer....